Inflammatory breast carcinoma. Effective multimodal approach

G. V. Burton, E. B. Cox, G. S. Leight Jr, L. R. Prosnitz, J. D. Iglehart, G. A. Olsen, H. F. Seigler and L. L. Hart
Department of Medicine, Duke University Medical Center, Durham, NC.

Twenty-two patients with inflammatory breast carcinoma received preoperative chemotherapy consisting of weekly administration of cyclophosphamide, doxorubicin hydrochloride, fluorouracil, and vincristine sulfate for six weeks. Postoperative therapy consisted of 22 weeks of biweekly administration of these drugs. Regional radiotherapeutic consolidation followed chemotherapy. Nineteen patients completed therapy. Twelve of these patients remain disease free (median, 15 months; range, four to 32 months). Median disease-free survival for all 22 patients is 13 months or more (range, zero to 32 months). Median overall survival is 18 months or more (range, one to 33 months). This regimen compares favorably with prolonged adjuvant and maintenance chemotherapy for inflammatory breast carcinoma.